Bioptimus

Cover Block

Name	Bioptimus
Tagline	Building universal AI foundation models for biology to simulate complex biological systems.
Headquarters	Paris, France
Founded	2024
Stage	Seed
Business Model	SaaS
Industry	Deeptech
Technology	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Corporate Spinout
Funding Label	Seed (total disclosed ~$35,000,000)

Links

• Website: https://www.bioptimus.com/
• LinkedIn: https://www.linkedin.com/company/bioptimus/

The Short Version

Bioptimus is building what it describes as the first universal AI foundation model for biology, an ambitious attempt to create a unified computational framework capable of simulating complex biological systems from molecules to whole organisms [Bioptimus]. The company, founded in 2024 by a team of former Google DeepMind and Owkin scientists, has secured a $35 million seed round led by Sofinnova Partners and Bpifrance [Mobihealthnews, March 2024]. Its core product, the M-Optimus model unveiled in December 2025, integrates multiple biological data types, including histology images, RNA sequencing, and clinical data, into a single architecture [PRNewswire, December 2025]. The business model is positioned as SaaS, targeting pharmaceutical, biotech, and academic research customers. Over the next 12-18 months, key watchpoints include the validation of M-Optimus's predictive capabilities through research partnerships, the scaling of its proprietary training dataset, and the translation of its technical vision into defined commercial workflows.

Data Accuracy: GREEN -- Core claims are corroborated by multiple independent sources.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	SaaS
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Corporate Spinout
Funding	Seed (total disclosed ~$35,000,000)

The Company in Brief

Bioptimus emerged in early 2024 as a corporate spinout from Owkin, with a founding team drawn from the intersection of Google DeepMind’s AI research and Owkin’s clinical data platform [Mobihealthnews, March 2024]. The company was incorporated in Paris, France, and publicly announced its launch alongside a $35 million seed round in March 2024 [TechCrunch, February 2024].

The company launched H-Optimus-1, a foundation model for pathology, in April 2025 [Bioptimus, April 2025]. Its most significant technical announcement to date came in December 2025 with the unveiling of M-Optimus, described as its inaugural multimodal world model for biology [PRNewswire, December 2025].

Data Accuracy: GREEN -- Confirmed by multiple press releases and investor announcements.

What They Have Built

Bioptimus describes its work as building a "world model of biology" that learns interactions across the multiple languages of biology, from molecular sequences to tissue images [Bioptimus, retrieved 2024]. The company's first public model, H-Optimus-1, launched in April 2025 as a foundation model specifically for pathology [Bioptimus, April 2025]. This was followed in December 2025 by the unveiling of M-Optimus, which integrates H&E histology images, bulk RNA-seq, spatial transcriptomics, and clinical data into a single architecture [PRNewswire, December 2025]. The stated goal is to create a universal framework capable of simulating disease mechanisms, predicting patient outcomes, and informing therapy design [Aipathly, retrieved 2024].

Technically, the wedge is the multimodal integration itself. Job postings for research scientists and engineers list required experience with PyTorch, large-scale distributed training, and multimodal learning [Greenhouse.io, retrieved 2026]. A key, publicly cited advantage is access to unique proprietary data at scale through its founders' ties to Owkin and associated clinical networks [Mobihealthnews, March 2024]. The recent appointment of a Chief Commercial Officer to focus on strategic partnerships indicates an enterprise-facing go-to-market motion is being developed [Bioptimus, retrieved 2024].

Data Accuracy: GREEN -- Product claims and model details are confirmed by company announcements and third-party press coverage.

Market Size and Demand

Bioptimus targets biomedical and life-science R&D, including pharmaceutical companies, biotechnology firms, and academic or clinical researchers [Aipathly, 2024]. The total addressable market can be approximated by the broader AI in drug discovery and development sector, which analysts at Grand View Research valued at $1.2 billion in 2022 and project to grow at a compound annual rate of 29.6% through 2030 [Grand View Research, 2023].

Metric	Value
AI in Drug Discovery Market (2022)	$1.2B
Projected CAGR (2023-2030)	29.6%

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report.

Who Else Is Fighting for This

Bioptimus enters a crowded field of AI-for-biology companies, positioning itself as the sole contender aiming for a universal, multimodal foundation model. Incumbent biopharma R&D software providers, like Schrödinger and Dassault Systèmes BIOVIA, offer established simulation suites but are not built on modern, large-scale foundation models. Primary challengers include venture-backed startups like Insitro, Recursion, and AbCellera. Adjacent substitutes include Google DeepMind's Isomorphic Labs and NVIDIA's BioNeMo platform.

Bioptimus's defensible edge rests on talent and proprietary data access. The founding team's background from Google DeepMind and Owkin provides credibility in AI research and applied biomedical data science [Mobihealthnews, March 2024]. The second edge is its claimed access to unique, multimodal datasets through its ties to Owkin's clinical network [Mobihealthnews, March 2024].

Opportunity

Bioptimus could become the default biological simulation engine for global pharmaceutical and biotechnology R&D. The company's stated ambition is to build a "universal framework" to simulate biology across scales [PRNewswire, December 2025]. The evidence that makes this reachable lies in the team's prior execution at Owkin and Google DeepMind [Mobihealthnews, March 2024].

Scenario	What happens	Catalyst	Why it's plausible
The Owkin Network Effect	Bioptimus becomes the exclusive or preferred AI engine for the vast network of academic hospitals and pharma partners already connected to Owkin.	A formal, announced strategic partnership or embedded offering between Bioptimus and Owkin.	The founding teams are deeply intertwined, with Jean-Philippe Vert and Olivier Elemento having led R&D and co-founded Owkin, respectively [Mobihealthnews, March 2024] [Sofinnova Partners].
The Regulatory & Clinical Endpoint Path	Bioptimus's models are adopted by regulatory bodies as a tool for validating digital biomarkers or synthetic control arms.	Publication of a landmark study in a top-tier journal demonstrating M-Optimus's predictive power.	The appointment of Julie Gerardi as Chief Commercial Officer signals an intent to engage with large, system-level stakeholders [Bioptimus].

Data Accuracy: YELLOW -- Core opportunity thesis is built on public company statements and team background.

Sources

1. [Bioptimus] Building the world model of biology | https://www.bioptimus.com/
2. [Mobihealthnews, March 2024] Bioptimus launches $35M to create AI foundation model for biology | https://www.mobihealthnews.com/news/bioptimus-launches-35m-create-ai-foundation-model-biology
3. [TechCrunch, February 2024] Bioptimus raises $35 million seed round to develop AI foundational model focused on biology | https://techcrunch.com/2024/02/20/bioptimus-raves-35-million-seed-round-to-develop-ai-foundational-model-focused-on-biology/
4. [PRNewswire, December 2025] Bioptimus unveils M-Optimus, a world model for biology | https://www.prnewswire.com/news-releases/bioptimus-unveils-m-optimus-a-world-model-for-biology-302644092.html
5. [Bioptimus, April 2025] Bioptimus launches H-Optimus-1: a state-of-the-art foundation model for pathology | https://www.bioptimus.com/news/bioptimus-launches-h-optimus-1
6. [Aipathly, retrieved 2024] Bioptimus company profile | https://www.aipathly.com/company/bioptimus
7. [The Manila Times, December 2025] Bioptimus unveils M-Optimus, a world model for biology | https://www.manilatimes.net/2025/12/17/business/bioptimus-unveils-m-optimus-a-world-model-for-biology/2083176
8. [Grand View Research, 2023] AI in Drug Discovery Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-drug-discovery-market
9. [Sofinnova Partners] Bioptimus portfolio page | https://sofinnovapartners.com/portfolio/bioptimus
10. [Greenhouse.io, retrieved 2026] Bioptimus job postings | https://job-boards.greenhouse.io/bioptimus8/jobs/4777680101